

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE NET SALES FROM CONTINUING OPERATIONS BY PRODUCT
QUARTERLY SALES TREND ANALYSIS
(\$ in millions)

	2008						2009						% Change		FX Impact			
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
TOTAL	4,188	4,475	8,663	4,510	13,173	4,542	17,715	4,322	4,665	8,987	4,788	13,775	5,033	18,808	11%	6%	4%	-2%
Cardiovascular	1,828	1,933	3,761	1,948	5,709	1,942	7,651	1,892	2,050	3,942	2,055	5,997	2,118	8,115	9%	6%	3%	-1%
Plavix	1,308	1,387	2,695	1,439	4,134	1,469	5,603	1,435	1,539	2,974	1,554	4,528	1,618	6,146	10%	10%	2%	-
Avapro/Avalide	305	335	640	334	974	316	1,290	302	313	615	329	944	339	1,283	7%	-1%	5%	-3%
Virology	734	791	1,525	824	2,349	812	3,161	794	848	1,642	890	2,532	981	3,513	21%	11%	4%	-4%
Reyataz	297	324	621	342	963	329	1,292	322	331	653	360	1,013	388	1,401	18%	8%	5%	-4%
Sustiva Franchise (a)	273	282	555	294	849	300	1,149	292	312	604	315	919	358	1,277	19%	11%	1%	-4%
Baraclude	108	136	244	144	388	153	541	152	179	331	191	522	212	734	39%	36%	5%	-4%
Oncology	436	474	910	447	1,357	462	1,819	407	450	857	447	1,304	437	1,741	-5%	-4%	3%	-1%
Eribitux	187	196	383	184	567	182	749	164	173	337	179	516	167	683	-8%	-9%	-	-
Sprycel	66	76	142	82	224	86	310	88	107	195	107	302	119	421	38%	36%	9%	-6%
Ixempra	25	26	51	25	76	25	101	24	29	53	28	81	28	109	12%	8%	-	-
Neuroscience	498	575	1,073	607	1,680	641	2,321	621	660	1,281	668	1,949	727	2,676	13%	15%	2%	-2%
Abilify (b)	454	529	983	564	1,547	606	2,153	589	643	1,232	653	1,885	707	2,592	17%	20%	2%	-2%
Immunoscience	87	106	193	119	312	129	441	124	148	272	162	434	168	602	30%	37%	2%	-2%
Orencia	87	106	193	119	312	129	441	124	148	272	162	434	168	602	30%	37%	2%	-2%
Metabolics	25	27	52	30	82	22	104	25	36	61	52	113	30	143	36%	38%	-1%	1%
Onglyza	-	-	-	-	-	-	-	-	-	-	20	20	4	24	N/A	N/A	N/A	N/A

* In excess of +/- 200%

(a) The Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla.

(b) Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.